TrialX
Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Barrett's Esophagus Clinical Trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,831 clinical trials

E Enriqueta Felip

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).

To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532. The MTDs will be defined based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period in studied regimens. The Recommended Dose …

18 years and older All Phase 1
O Onno Akkerman, MD

Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops

Rationale: Multidrug-resistant tuberculosis (MDR-TB) is defined as tuberculosis resistant to isoniazid and rifampicin. The incidence of MDR-TB worldwide is 3.9% for new cases and 21% for previously treated cases. However, the incidence of previously treated cases can rise to above 50% in eastern European countries. With increasing frequency of MDR-TB …

18 years and older All Phase 1
M Matthias Heinzl, MD

Cardiometabolic Effects of Rapid Glucose Excursion

The effects of rapid glucose excursions, induced by intravenous bolus application of glucose in healthy probands, on cardiometabolic and inflammatory parameters will be investigated

18-40 years Male Phase N/A
E Elisabeth Merkel

Gene Therapy for Fanconi Anemia Complementation Group A

The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A). Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the …

1 years and older All Phase 2
G Guopei Zhu, M.D

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy. The objective response rate (ORR) and …

18-75 years All Phase 2
J José Alegre Tamariz, MsC

Gait Re-education Program in Subjects With Parkinson´s Disease

Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called "TAPIZ FISIOR"- motor control and learning …

50 years and older All Phase N/A
L Lili Chen

Safety Tolerability and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198

This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

18-49 years All Phase 1
L Lili Chen

Safety Tolerability and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

This is a phase 1 study in which healthy adult volunteers will receive BRII-196 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

18-49 years All Phase 1
D Daiichi Sankyo Contact for Clinical Trial Information

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.

18-75 years All Phase N/A
B BrUOG

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical study in adult patients with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable …

18 years and older Male Phase 1/2

Simplify language using AI